Pressure BioScience (OTCQB: PBIO) is a leader in the
development and sale of broadly enabling, pressure-based instruments,
consumables, and platform technology solutions to the worldwide biotechnology,
biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage
industries. On April 29, PBIO announced its entrance into a binding letter of
intent to acquire Cannaworx Inc. (http://ibn.fm/TfZgu).
An article discussing the company reads, “The merged entity, equipped with an
extensive intellectual property portfolio utilizing a proprietary pressure
platform, nanotechnology and advanced delivery systems, plans to disrupt a
number of major world markets. These include the international cosmetics
market, projected to reach $758 billion by 2025 (http://ibn.fm/5N4vZ); the global agricultural technology
and products market, projected at $729 billion by 2023 (http://ibn.fm/XLNAf); the global
biopharmaceuticals market, expected to reach $389 billion by 2024 (http://ibn.fm/7VJpy); as well as
the U.S. hemp-derived CBD market, anticipated to reach $23.7 billion by
2023 (http://ibn.fm/4bLkg).
. . . Cannaworx’s diverse portfolio of products and intellectual property was
developed by its founders Bobby Ghalili, DMD, and Adrienne Denese, MD, PhD.
Ghalili and Denese bring extensive medical expertise and product innovation
into the newly combined public company. They have an impressive multiyear track
record of developing and selling personal-care and nutrition products.”
To view the full article, visit http://ibn.fm/doJ5a
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale
of innovative, broadly enabling, pressure-based solutions for the worldwide
life-sciences industry. The company’s products are based on the unique
properties of both constant (i.e., static) and alternating (i.e.,
pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented,
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics characterization
and quality control, soil and plant biology, forensics and counter-bioterror
applications. Additionally, major new market opportunities have emerged in the
use of its pressure-based technologies in the following areas: (1) the use of
its recently acquired, patented technology from BaroFold Inc. (the “BaroFold”
technology) to allow entry into the biopharma contract services sector, and (2)
the use of its recently patented, scalable, high-efficiency, pressure-based
Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and (ii) prepare
higher-quality, homogenized, extended shelf-life or room-temperature, stable,
low-acid liquid foods that cannot be effectively preserved using existing
nonthermal technologies. For more information, visit the company’s website
at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
